PRESS RELEASE published on 05/19/2025 at 07:51, 11 months 16 days ago AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle AB Science reçoit un brevet chinois pour le masitinib dans le traitement du COVID-19 jusqu'en 2041, renforçant sa protection en propriété intellectuelle COVID-19 Propriété Intellectuelle AB Science Masitinib Brevet Chinois
PRESS RELEASE published on 05/19/2025 at 07:51, 11 months 16 days ago AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research Intellectual Property COVID-19 Treatment AB Science Masitinib Chinese Patent
BRIEF published on 05/01/2025 at 10:11, 1 year ago AB Science reporte la publication de son rapport financier annuel 2024 Euronext Paris Rapport Financier Publication Retardée AB Science Masitinib
BRIEF published on 05/01/2025 at 10:11, 1 year ago AB Science postpones the publication of its 2024 annual financial report Euronext Paris Financial Report Publication Delayed AB Science Masitinib
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year ago AB Science publiera son rapport financier annuel 2024 le vendredi 9 mai 2025 AB Science annonce le report de la publication de son rapport financier annuel 2024 au 9 mai 2025 pour achever l'audit. La société se spécialise dans les inhibiteurs de protéines kinases Rapport Financier Audit AB Science Masitinib Inhibiteurs De Protéines Kinases
PRESS RELEASE published on 05/01/2025 at 10:06, 1 year ago AB Science will publish its 2024 annual financial report on May 9, 2025 AB Science postpones the publication of its 2024 annual financial report to May 9, 2025, to allow auditors more time for audit work. The report will be released after trading hours Financial Report Postponement Auditors AB Science 2024 Annual Report
BRIEF published on 04/23/2025 at 19:04, 1 year ago EMA Grants Orphan Drug Status to AB8939 for AML Treatment AB Science AB8939 EMA Approval Acute Myeloid Leukemia Orphan Designation
BRIEF published on 04/23/2025 at 19:04, 1 year ago L'EMA accorde le statut de médicament orphelin à AB8939 pour le traitement de la LAM AB Science AB8939 Approbation De L'EMA Leucémie Myéloïde Aiguë Désignation D'orphelin
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year ago AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia AB Science's AB8939 granted orphan drug designation by EMA in EU for treating acute myeloid leukemia, showing significant benefit over current therapies. Preclinical data reveals efficacy and safety Orphan Drug Designation AB Science EMA AB8939 Acute Myeloid Leukemia
PRESS RELEASE published on 04/23/2025 at 18:59, 1 year ago La molécule AB8939 obtient la désignation de médicament orphelin auprès de l'EMA dans le traitement de la leucémie myéloïde aigue La molécule AB8939 obtient la désignation de médicament orphelin dans l'Union Européenne pour le traitement de la leucémie myéloïde aigüe. AB Science fait un pas important dans le domaine de la recherche médicale Traitement AB Science Médicament Orphelin AB8939 Leucémie Myéloïde Aiguë
Published on 05/04/2026 at 16:45, 3 hours 20 minutes ago Inventus Announces Engagement of Red Cloud Securities
Published on 05/04/2026 at 16:27, 3 hours 38 minutes ago Avenir Minerals to Acquire Fox River Resources in All-Cash Transaction for Approximately C$94.3 Million
Published on 05/04/2026 at 15:30, 4 hours 35 minutes ago Silver Spruce Resources Announces Resumption of Exploration at its Melchett Lake Au-Ag-Zn-Pb-Cu Volcanogenic Massive Sulphide Project, Nakina, Ontario
Published on 05/04/2026 at 15:00, 5 hours 5 minutes ago Shelfie Signs Definitive Agreement to Acquire Majority Interest in Israeli Based Aspect Information Systems Ltd.
Published on 05/04/2026 at 14:46, 5 hours 19 minutes ago Worksport (NASDAQ:WKSP) Invited to Present at D. Boral 2026 Global Conference
Published on 05/04/2026 at 19:30, 34 minutes ago Shareholders approve all proposals – Dr Annelise Lüscher Hämmerli and Urs Simeon elected to the Board of Directors
Published on 05/04/2026 at 19:00, 1 hour 4 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 27 AVRIL 2026 au 01 MAI 2026
Published on 05/04/2026 at 19:00, 1 hour 5 minutes ago L’Assemblée générale 2026 approuve toutes les propositions du Conseil d’administration
Published on 05/04/2026 at 19:00, 1 hour 5 minutes ago Shareholders approve all Board proposals at Annual General Meeting
Published on 05/04/2026 at 18:00, 2 hours 4 minutes ago PURE Swiss Opportunity REF (PSO) Key details of the capital increase in May 2026
Published on 05/04/2026 at 19:05, 1 hour ago CP -Mise en œuvre d’un contrat de liquidité avec INVEST SECURITIES
Published on 05/04/2026 at 18:19, 1 hour 45 minutes ago Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 05/04/2026 at 17:59, 2 hours 5 minutes ago Saint-Gobain has signed an agreement for the sale of its distribution business in Brazil
Published on 05/04/2026 at 17:59, 2 hours 5 minutes ago Saint-Gobain signe un accord de cession de son activité de distribution au Brésil
Published on 05/04/2026 at 17:45, 2 hours 20 minutes ago Déclaration hebdomadaire de rachat d'actions